Pneumococcal vaccine

Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

Retrieved on: 
Friday, July 16, 2021
Health, FDA, Infectious diseases, Fitness & Nutrition, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Pneumonia, Clinical medicine, Medicine, Vaccination, Vaccines, Pneumococcal vaccine, Pneumococcal conjugate vaccine, Streptococcus pneumoniae, Vaccine, Immunization, Pneumococcal polysaccharide vaccine, VAXNEUVANCE, Merck, VAXNEUVANCE, MERCK

Invasive pneumococcal disease (IPD) occurs when the bacteria infect parts of the body that are usually free from germs.

Key Points: 
  • Invasive pneumococcal disease (IPD) occurs when the bacteria infect parts of the body that are usually free from germs.
  • VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by the S. pneumoniae serotypes contained in the vaccine.
  • VAXNEUVANCE previously received Breakthrough Therapy designation from the FDA for the prevention of IPD in adults 18 years of age and older.
  • Adults 18-49 years of age with no history of pneumococcal vaccination, including individuals at increased risk of developing pneumococcal disease.

Global Pneumococcal Vaccine Market (2021 to 2026) - by Type of the Vaccine, Product, Sectors, Distribution Channel and Geography - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 16, 2021
Biotechnology, Pharmaceutical, Health, Medical specialties, Vaccination, Microbiology, Clinical medicine, Pneumonia, Pneumococcal vaccine, Vaccines, Vaccine, Streptococcus pneumoniae, Gavi

The "Global Pneumococcal Vaccine Market (2021-2026) by type of the Vaccine, Product, Sectors, Distribution Channel, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pneumococcal Vaccine Market (2021-2026) by type of the Vaccine, Product, Sectors, Distribution Channel, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pneumococcal Vaccine Market is estimated to be USD 8.4 Bn in 2021 and is expected to reach USD 11.8 Bn by 2026, growing at a CAGR of 7%.
  • The factors such as the rising prevalence of pneumococcal diseases amongst the population and the introduction of novel vaccines have supported the growth of the market.
  • The growing awareness programs about pneumococcal diseases initiated by the Government are also boosting the market growth.

U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

Retrieved on: 
Wednesday, June 9, 2021
Research, Medical Supplies, Infectious diseases, FDA, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Pneumonia, Medical specialties, Clinical medicine, Health care, Pneumococcal conjugate vaccine, Vaccines, Vaccination, Pneumococcal vaccine, Ruth Link-Gelles, 20-Valent Pneumococcal Conjugate Vaccine Regulatory Review, Pfizer: Breakthroughs That Change Patients’ Lives, 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE REGULATORY REVIEW, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

With a single injection, PREVNAR 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world.

Key Points: 
  • With a single injection, PREVNAR 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world.
  • Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
  • Coverage of Next Generational Pneumococcal Conjugate Vaccines for Invasive Pneumococcal Disease in Older Adults of High-Income Countries.
  • Current and future pneumococcal conjugate vaccine serotype-specific burden in the United States adult population.

Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Pneumonia, Pneumococcal conjugate vaccine, Clinical medicine, Health care, Vaccine, Conjugate vaccine, Vaccines, Pneumococcal vaccine, Vaccination schedule

A live webcast of the presentation can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .

Key Points: 
  • A live webcast of the presentation can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .
  • A replay of the webcast will be available for approximately 30 days following the conference.
  • Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
  • Vaxcytes lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD).

Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine

Retrieved on: 
Thursday, May 20, 2021
Health, Infectious diseases, Clinical trials, General Health, Pharmaceutical, Biotechnology, Pneumonia, Medical specialties, Clinical medicine, Microbiology, Pneumococcal conjugate vaccine, Pneumococcal infection, Vaccine, Pneumococcal vaccine, Streptococcus pneumoniae, Conjugate vaccine, PNEU-DIRECTION, PNEU-PLAN, V114, Pneumococcal Disease, Merck, PNEU-DIRECTION, PNEU-PLAN, V114, PNEUMOCOCCAL DISEASE, MERCK

\xe2\x80\x9cAt Merck, our goal is to expand coverage to new serotypes not targeted by currently available pediatric pneumococcal conjugate vaccines, while maintaining a strong immune response to current vaccine serotypes so as to help sustain progress achieved to date.

Key Points: 
  • \xe2\x80\x9cAt Merck, our goal is to expand coverage to new serotypes not targeted by currently available pediatric pneumococcal conjugate vaccines, while maintaining a strong immune response to current vaccine serotypes so as to help sustain progress achieved to date.
  • Children under the age of 2 are particularly vulnerable to pneumococcal infection and invasive pneumococcal disease incidence remains highest in the first year of life.
  • Serotypes 22F, 33F and 3 represent a sizeable portion of invasive pneumococcal disease cases in adults and children.
  • This supports the need for robust immune suppression of current vaccine serotypes while also expanding serotype coverage.

Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 11, 2021
Medical specialties, Pneumonia, Vaccination, Pneumococcal conjugate vaccine, Clinical medicine, Health care, PCV, Vaccine, Conjugate vaccine, Vaccines, Pneumococcal vaccine

Mrs. Graesser brings to Vaxcyte over 20 years of healthcare communications experience and expertise across a variety of areas, including corporate communications and strategy, public relations and organizational communications.

Key Points: 
  • Mrs. Graesser brings to Vaxcyte over 20 years of healthcare communications experience and expertise across a variety of areas, including corporate communications and strategy, public relations and organizational communications.
  • Vaxcyte\xe2\x80\x99s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease.
  • Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
  • Readers should not rely upon the information in this press release as current or accurate after its publication date.\n'

Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease

Retrieved on: 
Monday, May 10, 2021
Pneumonia, Medical specialties, Microbiology, Clinical medicine, Pneumococcal conjugate vaccine, PCV, Streptococcus pneumoniae, Vaccine, Conjugate vaccine, Pneumococcal vaccine

\xe2\x80\x9cThese preclinical data add to the growing body of evidence supporting the potential for VAX-24, using Vaxcyte\xe2\x80\x99s proprietary cell-free protein synthesis platform, to become the broadest-spectrum PCV.

Key Points: 
  • \xe2\x80\x9cThese preclinical data add to the growing body of evidence supporting the potential for VAX-24, using Vaxcyte\xe2\x80\x99s proprietary cell-free protein synthesis platform, to become the broadest-spectrum PCV.
  • Antibiotics are used to treat pneumococcal disease, but some strains of the bacteria have developed resistance to treatments.
  • Vaxcyte\xe2\x80\x99s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease.
  • Readers should not rely upon the information in this press release as current or accurate after its publication date.\n'

Vaxcyte to Present at BofA Securities 2021 Health Care Conference

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Pneumococcal conjugate vaccine, Pneumonia, Vaccine, Health care, Clinical medicine, Pneumococcal vaccine, Vaccination schedule, Medical specialties, Pneumococcal conjugate vaccine, Pneumonia, Vaccine, Health care, Clinical medicine, Pneumococcal vaccine, Vaccination schedule

b'FOSTER CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will present at the BofA Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 3:30pm ET.\nA live webcast of the presentation can be accessed through the Investors & Media section of the Company\xe2\x80\x99s website at http://investors.vaxcyte.com .

Key Points: 
  • b'FOSTER CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will present at the BofA Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 3:30pm ET.\nA live webcast of the presentation can be accessed through the Investors & Media section of the Company\xe2\x80\x99s website at http://investors.vaxcyte.com .
  • A replay of the webcast will be available for approximately 30 days following the conference.\nVaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
  • Vaxcyte\xe2\x80\x99s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD).
  • For more information, visit www.vaxcyte.com .\n'

Global Pneumococcal Vaccines Disease Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 7, 2021
Health, Pharmaceutical, Vaccines, Medical specialties, Health care, Pneumococcal conjugate vaccine, Health, Pneumococcal vaccine, Vaccine, Pneumococcal polysaccharide vaccine, Maria Deloria Knoll

The "Disease Analysis: Pneumococcal Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Pneumococcal Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • The changing epidemiology of pneumococcal disease has influenced vaccine and dosing recommendations in the US and UK.
  • Both vaccines possess broader serotype coverage than the currently recommended Prevnar 13 and hope to benefit commercially from serotype shift in pneumococcal disease incidence.
  • Pneumococcal vaccines, on average, take 8.6 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.

Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Monday, April 5, 2021
Vaccines, Medical specialties, Health care, Pneumococcal conjugate vaccine, Medicine, Vaccine, Conjugate vaccine, Pneumococcal vaccine, Vaccination schedule

A live webcast of the fireside chat can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .

Key Points: 
  • A live webcast of the fireside chat can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .
  • A replay of the webcast will be available for approximately 30 days following the conference.
  • Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
  • Vaxcytes lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD).